Skip to content

Evaluation of intravenous magnesium sulphate in clinical imrovement of patients, with acute stroke, in Ardabil Alavi hospital

Evaluation of intravenous magnesium sulphate in clinical improvement of patients, with acute stroke

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014060117945N1
Enrollment
80
Registered
2014-07-20
Start date
2013-08-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke. Accident - vascular, brain

Interventions

Intervention 1: In the control group the same amount of volume, not weight of normal saline solution over 15 minutes and then within 24 hours for patient was given. Intervention 2: In the intervention
Placebo
Treatment - Drugs
In the control group the same amount of volume, not weight of normal saline solution over 15 minutes and then within 24 hours for patient was given.
In the intervention group magnesium sulfate vials has been given for the patient that have stroke in last 12 hour, 4 g intravenous magnesium sulfate in less than 15 minute and then 16 g within 24 hour

Sponsors

Ardabil University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age greater than 18 years old; Age less than 80 years old; onset of symptoms less than 12 hour . Exclusion criteria: : Patient with chronic renal failure (more than 5.2); pregnant patients; patients with brain hemorrhage; age less than 18 years old; systolic blood pressure greater than 220 and diastolic lower than 90; patient with severe respiratory disease; patient with heart block; Patients with pre-existing neurological disease or progressive systemic disease that can impair neurological assessment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Degree of limb paresis. Timepoint: Admission - three days later - two weeks later. Method of measurement: Standard questionnaire NIHSS.;Aphasia. Timepoint: Admission - three days later - two weeks later. Method of measurement: Standard questionnaire NIHSS.;Level of consciousness. Timepoint: Admission - three days later - two weeks later. Method of measurement: Standard questionnaire NIHSS.

Secondary

MeasureTime frame
The rate of cerebral ischemia. Timepoint: 3 day later - 2 week later. Method of measurement: CT-scan.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ghasem Fattahzadeh Ardalani

Ardabil University of Medical Sciences

Gh.fattahzadeh@arums.ac.ir+98 45 1224 8888

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026